Figure 2 | Scientific Reports

Figure 2

From: Inhibition of DNMT3B expression in activated hepatic stellate cells overcomes chemoresistance in the tumor microenvironment of hepatocellular carcinoma

Figure 2

Drug screening of anti-fibrotic compounds in MCHSs. (A) Size and Huh7.5-RFP intensity of MCHSs treated with 0.5% DMSO (negative control) or 10 µM OCA (positive control). (B) The effects of 9695 drugs on MCHS size were evaluated. (C) The MCHS size was evaluated after treatment with different concentrations of CHIR-99021, CHIR-98014, and GW4064 starting at 10 µM. (D) Other GSK3β inhibitors in the compound library, such as SB-216763, TWS-119, Tideglusib, and SB-415286 (1 µM) were used to treat MCHSs. The spheroid size was calculated.

Back to article page